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Abstract Objective: The computer-adaptive test (CAT) of the European Organisation for
Research and Treatment of Cancer (EORTC), the EORTC CAT Core, assesses the same 15
domains as the EORTC QLQ-C30 health-related quality of life questionnaire but with
increased precision, efficiency, measurement range and flexibility. CAT parameters for esti-
mating scores have been established based on clinical data from cancer patients. This study
aimed at establishing the European Norm for each CAT domain based on general population
data.
Methods: We collected representative general population data across 11 European Union
(EU) countries, Russia, Turkey, Canada and the United States (n  1000/country; stratified
by sex and age). We selected item subsets from each CAT domain for data collection (totalling
86 items). Differential item functioning (DIF) analyses were conducted to investigate cross-
cultural measurement invariance. For each domain, means and standard deviations from
the EU countries (weighted by country population, sex and age) were used to establish a T-
metric with a European general population mean Z 50 (standard deviation Z 10).
Results: A total of 15,386 respondents completed the online survey (n Z 11,343 from EU
countries). EORTC CAT Core norm scores for all 15 countries were calculated. DIF had
negligible impact on scoring. Domain-specific T-scores differed significantly across countries
with small to medium effect sizes.
Conclusion: This study establishes the official European Norm for the EORTC CAT Core.
The European CAT Norm can be used globally and allows for meaningful interpretation of
scores. Furthermore, CAT scores can be compared with sex- and age-adjusted norm scores
at a national level within each of the 15 countries.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The assessment of health-related quality of life
(HRQoL) using patient-reported outcome (PRO) mea-
sures has become increasingly important to evaluate,
monitor and improve the quality of cancer care [1e3].
One of the most frequently used PRO measures for
cancer patients is the European Organisation for
Research and Treatment of Cancer (EORTC) Quality of
Life core questionnaire QLQ-C30 [4,5]. It consists of 30
items covering five multi-item function scales (physical,
role, social, cognitive and emotional function), three
multi-item symptom scales (fatigue, nausea/vomiting
and pain), six single-item scales assessing further aspects
of HRQoL (dyspnoea, insomnia, appetite loss, con-
stipation, diarrhoea and financial difficulties) and a scale
on overall health/HRQoL.
The QLQ-C30 has been evaluated in many different
cancer populations, and adequate psychometric prop-
erties were largely supported [6]. However, some
studies found floor and ceiling effects [7,8]. Also, it is a
well-known limitation of traditional HRQoL ques-
tionnaires, such as the QLQ-C30, that some questions
might be irrelevant to the patient, which potentially
increases respondent burden and results in less precise
score estimates [9]. A promising solution to overcome
such limitations is the use of computer-adaptive tests
(CATs). CAT is methodologically based on item
response theory (IRT). Using IRT, domain-specific
item banks (i.e. lists of items measuring the same
domain) can be calibrated on a common scale [9,10].
Fitting an IRT model provides item parameters that
reflect the statistical relationship between an in-
dividual’s response to a given item and his/her position
on a domain scale. A major advantage of using IRT for
scoring is that any item subset of an item bank can be
used to estimate a person’s domain score on the same
continuous metric [11]. This enables CATs, in which
HRQoL assessment is tailored to the individual, which
increases measurement precision and range while
reducing respondent burden, sample size requirements
and study costs [10,12,13].
In 2006, the EORTC Quality of Life Group started
developing the EORTC CAT Core, which is based on
domain-specific item banks measuring the same di-
mensions as the QLQ-C30 [14,15]. In the item bank
development process, different sources of information
were collated, including literature reviews, qualitative
input from various stakeholders and psychometric an-
alyses of large international samples of cancer patients
[14]. Item bank development for all domains was
completed in 2016 [12,16e22]. To calibrate items of each
bank, IRT models were estimated using data obtained
from these clinical samples [22]. After item calibration,
parameters are based on a z-score metric with a study
population mean of 0 and standard deviation (SD) of 1.
Such scores are ‘arbitrary’, hampering interpretation.
Thus, the next step of item calibration is to link the CAT
algorithm to general population norm data to simplify
score interpretation. In this final step, it has become
common practice to transform scores to a T-score metric
with a general population mean of 50 (SD Z 10).
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The EORTC CAT Core development did not include
this final step of transforming scores to T-scores.
Therefore, for a more meaningful and sensible score
interpretation, this study aimed at collecting represen-
tative data of the European general population to
transform the current scoring to a T-score metric. Any
score obtained via the EORTC CAT Core can then be
interpreted in relation to this European mean. In addi-
tion, CAT norm scores are established for sex-, age- and
country-specific subpopulations.
2. Methods
2.1. Sampling
To collect general population data to establish the
‘European CAT Norm’, we subcontracted GfK SE
(http://www.gfk.com/). Data were collected via online
surveys in March/April 2017 in 11 European Union
(EU) countries (Austria, Denmark, France, Germany,
Hungary, Italy, the Netherlands, Poland, Spain,
Sweden and the United Kingdom), Russia, Turkey,
Canada and the United States for comparative
purposes. We stratified data collection by sex and age
groups (18e39, 40e49, 50e59, 60e69, 70þ years),
with a target sample size of each sex  age  country
subgroup of n Z 100, leading to an anticipated
sample size of n Z 1000/country. Assuming a T-scale
with a mean Z 50 (SD Z 10), this sample size allows
for estimating the population T-score mean of each
country (n Z 1000) within 0.6 T-scores (95%
confidence interval), which was considered to be
sufficiently precise. Moreover, this sampling design is
sufficient to investigate differential item functioning
(DIF) using logistic regression analysis [23].
2.2. Selection of items
The full item pool of the EORTC CAT Core consists of
14 item banks for the function and symptom-related
HRQoL domains in the QLQ-C30 plus two global items
forming the 15th scale for overall HRQoL. The number
of items per bank ranges between 7 (appetite loss) and 34
items (fatigue, cognitive function). In total, 260 items are
available for CAT assessment. For establishing CAT
norm values, 86 items were selected, consisting of all
QLQ-C30 items plus four additional items per domain
(56 items). The selection of the 56 items was based on
high measurement precision and adequate range of
measurement as indicated by the items’ psychometric
properties and content validity considerations, that is,
all aspects of a given domain had to be covered.
2.3. Differential item functioning
DIF analyses are used to evaluate whether items mea-
sure the same underlying construct in different
subpopulations [24], a central requirement for estab-
lishing a common norm across subpopulations. We
investigated DIF regarding country, sex and age groups
using ordinal logistic regression [23,25]. A regression
was modelled for each item, with the item response as
the dependent variable and the IRT-based domain score
as the independent variable. If adding the grouping
variable of interest (country/sex/age) to this model as an
independent variable leads to a change in the Nagel-
kerke R2 coefficient .035, this indicates potentially
relevant DIF [20,26]. If DIF was identified, we evaluated
its practical importance by calculating the standardised
mean difference (SMD) between scores derived from all
available items of a domain versus scores derived from a
reduced item set, that is, excluding items showing DIF.
If SMD was .2 (small effect size [ES] [27]), the practical
impact of DIF was considered to be negligible and
affected items were kept.
2.4. Establishing the European CAT norm
For establishing the ‘European CAT Norm’, we used
general population data from the 11 EU countries. In a
first step, we scored the data based on the previously
established ‘arbitrary’ IRT-based z-score metric and
calculated means/SDs for each CAT domain. To correct
for over- or under-representation of subgroups, we
weighted scores by country population size, sex and age
distribution, with the youngest age group further
divided into 18e29 and 30e39 years. Individual
weighting factors were calculated for each country  sex
 age group based on general population distribution
statistics for 2015 [28] using the formula:
Weighting factor Z percentage of subgroup in population/
percentage of subgroup in sample.
After estimating weighted means and SDs, scores
were transformed to a T-score metric using linear
transformation to establish the ‘European CAT Norm’
with mean Z 50 and SD Z 10 using the formula:
T-scoreZ10  ðz-score z-score meanÞ=z-score SDþ 50:
Using these formulas, we calculated European norm
scores (means, SDs) for each CAT domain overall and
by sex and age. Furthermore, to establish norm scores
for each of the 15 countries, national T-score means/SDs
were calculated using country-specific sex- and age-
weighting factors.
2.5. Determining the extent of subgroup differences
For each CAT domain, we investigated T-score differ-
ences between countries, sex, age groups and dicho-
tomised educational levels (less than postcompulsory
education and at least some postcompulsory education).
We conducted covariance analyses for each independent
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variable, entering the remaining three variables as
covariates. When used as a covariate, age was entered as
continuous variable. Statistical significance was implied
by P value <.01. We interpreted partial eta2 values of
.01 (zR2 Z 1%), .06 (zR2 Z 6%) and .14
(zR2 Z 14%) as small, medium and large ES, respec-
tively [27].
For analysing DIF, R 3.1.2 was applied using the
package lordif version 0.3-3 [25,29]. For all other sta-
tistical analyses, we used IBM SPSS Statistics, version
22 [30].
3. Results
3.1. Sample
The total sample size was NZ 15,386 for the full sample
and n Z 11,343 for the EU sample (Table 1). Further
details on sampling and sociodemographic data are
provided elsewhere [35].
3.2. Psychometric properties
DIF by country and age was detected in two items of the
physical function (PF) scale. As the ES of excluding
versus including the DIF-items when estimating PF
scores in the full sample were very small (SMD Z .01),
all items of the PF scale were retained for further ana-
lyses. For the Hungarian data, one item of the sleep
problems scale (SL4) had to be excluded from further
analyses due to a translation error.
3.3. European CAT norm scores
Table 2 presents domain-specific z-score distributions in
the EU countries, weighted by country population size,
sex and age. In all CAT domains, except for dyspnoea,
all mean scores indicate better HRQoL in the general
population compared with scores in the original cancer
populations (which by way of model estimation has
mean Z 0).
In Table 3, the final European CAT Norm T-scores
(means and SDs) for each domain are reported for the
EU sample overall (by definition with mean Z 50) and
by sex and age. Covariance analyses indicated higher
HRQoL in men than in women (P < .001) in all do-
mains but ES were small, ranging from eta2 Z .001 for
diarrhoea and nausea/vomiting to eta2 Z .020 and .022
for emotional function and PF, respectively. Age also
had a statistically significant effect on HRQoL (P < .001
for each domain); however, the relational patterns were
inconsistent across CAT scales, and ES were small for
most domains, ranging from eta2 Z .002 for pain to
eta2 Z .020 for fatigue. In three domains, a larger and
relatively linear age effect was found: emotional function
(eta2 Z .047) and nausea/vomiting (eta2 Z .034)
improved while PF scores (eta2 Z .066) worsened with
age.
Except for diarrhoea, scores were also significantly
associated with educational level (P < .01) with higher
educated individuals reporting better HRQoL scores
(data not shown). However, these ES were very small
(all eta2  .015).
Table 4 presents CAT T-scores for all 15 countries.
Within EU countries, domain scores in Poland indicated
relatively low HRQoL, while scores were comparatively
high in Austria and the Netherlands. In the United
States and Canada, score distributions were relatively
Table 1
EORTC CAT Core general population norm data sample
characteristics.
Sociodemographic variable Full sample
(15 countries;
N Z 15,386)
Norm sample
(11 EU countries;
n Z 11,343)
n (%) n (%)
Age, years
18e29 1177 (7.6) 883 (7.8)
30e39 1902 (12.4) 1370 (12.1)
40e49 3049 (19.8) 2248 (19.8)
50e59 3059 (19.9) 2253 (19.9)
60e69 3138 (20.4) 2337 (20.6)
70þ 3061 (19.9) 2252 (19.9)
Sex
Female 7650 (49.7) 5623 (49.6)
Male 7736 (50.3) 5720 (50.4)
Education
Less than compulsory education 183 (1.2) 95 (.8)
Compulsory (left school at the
minimum school leaving age)
1509 (9.8) 897 (7.9)
Some postcompulsory (some
school after reaching school
leaving age without reaching
university entrance
qualifications [e.g. A levels])
2050 (13.3) 1954 (17.2)
Postcompulsory below
university (e.g. reaching A
levels)
4405 (28.6) 3408 (30.0)
University degree (bachelor’s or
equivalent level)
3716 (24.2) 2689 (23.7)
Postgraduate degree (master’s,
doctorate or equivalent level)
3337 (21.7) 2131 (18.8)
Prefer not to answer 186 (1.2) 169 (1.5)
Country
Austria 1002 (6.5) 1002 (8.8)
Denmark 1003 (6.5) 1003 (8.8)
France 1001 (6.5) 1001 (8.8)
Germany 1006 (6.5) 1006 (8.9)
Hungary 1053 (6.8) 1053 (9.3)
Italy 1036 (6.7) 1036 (9.1)
The Netherlands 1000 (6.5) 1000 (8.8)
Poland 1024 (6.7) 1024 (9.0)
Spain 1165 (7.6) 1165 (10.3)
Sweden 1027(6.7) 1027 (9.1)
The United Kingdom 1026 (6.7) 1026 (9.0)
Russia 1007 (6.5) e
Turkey 1023 (6.6) e
Canada 1004 (6.5) e
The United States 1009 (6.6) e
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similar to the EU countries. In contrast, mean scores of
the Russian and Turkish general populations indicated
worse HRQoL in most CAT domains compared to the
EU average. In the covariance analyses, T-scores
differed significantly across countries in all CAT do-
mains (P < .001). However, ES were small for each
domain (eta2 < .06).
4. Discussion
The EORTC CAT Core is the first disease-specific
computer-adaptive PRO assessment system developed
across different countries for measuring a wide range of
HRQoL aspects relevant to cancer patients. In an
extensive development and psychometric evaluation
process, the EORTC CAT has been proven to be a more
precise, efficient and flexible measurement instrument
compared to the traditional QLQ-C30 static question-
naire [22].
This study established the official ‘European CAT
Norm’ based on general population data from 11 EU
countries for a more meaningful and sensible interpre-
tation of EORTC CAT scores. The domain-specific
means and SDs presented herein are now implemented
in the EORTC CAT scoring algorithm using a stand-
ardised scale centred to the European general popula-
tion with a mean of 50 (SD Z 10). Additionally, we
present norm scores per country and for sex- and age-
specific subgroups. This allows for a meaningful and
detailed interpretation of cancer patients’ scores.
Similar to our findings presented in the EORTC
QLQ-C30 norm data paper [35], some group differences
were observed. For example, men tended to score
somewhat better than women, which is consistent with
other QLQ-C30 norm data studies [31]. Furthermore,
some observed age differences were counterintuitive,
with the youngest participants showing lowest/worst
scores in some function scales, which has also been
observed by others in the application of item banks [32].
Due to these group differences, we recommend the use
of sex- and age-matched norm data for the most sensible
and meaningful score interpretation of data from cancer
patients obtained via the EORTC CAT Core.
The observed differences between countries need to
be taken at face value. It is conceivable that these dif-
ferences reflect ‘true’ differences in HRQoL; however, it
is also possible that some of these differences either
reflect differences due to slightly different meanings
between language versions or they reflect cultural dif-
ferences, for example, in terms of culture-related health
perceptions, expectations or response styles. Given the
vast experience with questionnaire translation and cul-
tural adaptation of items at the EORTC headquarters
and findings in the literature showing language-related
DIF to be negligible [33], we assume the observed dif-
ferences to be ‘true’ country differences in HRQoL until
further evidence is found that supports or refutes our
hypothesis. Furthermore, our tests of country-DIF as
presented herein show minimal impact of DIF,
providing sufficient support for our assumption of true
intercountry differences.
Our study has some limitations. First, it is not clear
whether online panels are truly representative of the
general population despite panel research companies
claiming they are. As an increasingly large proportion of
people have access to the Internet, the potential problem
of representativeness is getting smaller but still remains,
especially in countries such as Turkey where GfK had to
carry out telephone interviews to achieve sampling
quotas (for details see [35]). Our data suggest represen-
tativeness regarding most sample characteristics except
for educational status; however, when testing for the
influence of educational level, we found that the prac-
tical consequences were negligible. These findings
Table 2
z-score distribution in the EU countries (n Z 11,343) of the EORTC CAT Core domain scales.
EORTC CAT Core domain Number of items Mean SD Median Minimum Maximum Skewness
Physical function 9 .2327 .81453 .1960 e2.69 1.51 e.312
Role function 6 .4491 .82772 .6990 e2.19 1.18 e.912
Emotional function 8 .0813 .98832 .0982 e2.76 1.38 e.394
Cognitive function 6 .2466 .97733 .3490 e2.98 1.24 e.777
Social function 6 .3203 .93293 1.0150 e2.62 1.02 e1.097
Fatigue 7 e.1346 .92938 e.1080 e1.45 2.42 .375
Nausea/vomiting 6 e1.8961 .78304 e2.2130 e2.21 2.14 2.748
Pain 6 e.8193 1.20929 e.9480 e2.03 2.43 .612
Dyspnoea 5 .1787 .94265 .2050 e.68 2.91 .674
Sleep problems 5 e.3120 1.08615 e.2320 e1.68 2.36 .461
Appetite loss 5 e.2141 .77220 e.6760 e.68 2.61 1.453
Constipation 5 e.4222 .74434 e.6020 e1.07 2.21 .928
Diarrhoea 5 e.4564 .67354 e.8460 e.85 2.20 1.535
Financial difficulties 5 e.3617 .78364 e.8310 e.83 2.38 1.497
Overall HRQoL 2 .1163 .93597 .0390 e2.58 1.91 e.089
EORTC CAT Z The computer-adaptive test of the European Organisation for Research and Treatment of Cancer; EU Z European Union;
HRQoL Z health-related quality of life. Bold values Z The z-score mean and SD values were used in the formula described in section 2.4 for
transforming the z-scores to T-scores.
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Table 3
European norm T-scores (based on 11 EU countries) for each EORTC CAT Core domain: mean scores (M ) and standard deviations (SDs) by sex and age groupsa.
Domain Full sample, M (SD) 18e29 years, M (SD) 30e39 years, M (SD) 40e49 years, M (SD) 50e59 years, M (SD) 60e69 years, M (SD) 70þ years, M (SD)
All Male Female All Male Female All Male Female All Male Female All Male Female All Male Female All Male Female
Physical function 50.00
(10.00)
51.52
(10.23)
48.56
(9.56)
52.83
(9.53)
53.75
(10.38)
51.86
(8.44)
52.54
(9.83)
53.82
(9.93)
51.23
(9.55)
51.47
(10.00)
52.95
(9.93)
49.99
(9.87)
49.34
(9.74)
50.89
(9.87)
47.83
(9.38)
47.40
(9.26)
48.60
(9.60)
46.30
(8.79)
45.36
(9.29)
47.24
(9.62)
44.02
(8.81)
Role function 50.00
(10.00)
50.44
(9.83)
49.59
(10.14)
51.20
(9.74)
50.12
(10.56)
52.32
(8.66)
50.91
(9.73)
51.16
(9.54)
50.66
(9.91)
50.78
(10.09)
51.26
(9.84)
50.29
(10.32)
49.78
(10.17)
50.59
(9.81)
48.99
(10.45)
49.48
(9.96)
50.13
(9.50)
48.89
(10.34)
47.47
(9.86)
49.16
(9.18)
46.27
(10.14)
Emotional function 50.00
(10.00)
51.19
(9.84)
48.88
(10.02)
48.50
(10.84)
49.86
(10.93)
47.09
(10.55)
48.21
(10.36)
48.98
(10.36)
47.42
(10.32)
49.19
(10.15)
50.40
(9.71)
47.96
(10.43)
49.71
(9.60)
51.05
(9.54)
48.40
(9.49)
52.16
(9.08)
53.40
(8.65)
51.02
(9.33)
52.92
(8.48)
54.81
(7.46)
51.57
(8.90)
Cognitive function 50.00
(10.00)
50.65
(10.04)
49.39
(9.93)
48.33
(11.11)
48.73
(11.57)
47.91
(10.61)
49.57
(10.93)
50.24
(10.83)
48.89
(10.99)
49.82
(10.35)
50.78
(10.08)
48.85
(10.53)
50.26
(9.78)
51.40
(9.66)
49.14
(9.78)
51.56
(8.45)
51.84
(8.41)
51.31
(8.49)
51.11
(8.15)
51.80
(7.74)
50.61
(8.40)
Social function 50.00
(10.00)
50.38
(9.84)
49.64
(10.14)
49.70
(10.44)
49.74
(10.58)
49.66
(10.30)
49.10
(10.60)
49.41
(10.53)
48.77
(10.67)
48.98
(10.55)
49.46
(10.20)
48.51
(10.87)
49.75
(10.06)
50.62
(9.67)
48.91
(10.36)
51.19
(9.21)
51.68
(8.84)
50.73
(9.53)
51.56
(8.44)
52.08
(7.95)
51.19
(8.75)
Fatigue 50.00
(10.00)
48.84
(9.81)
51.10
(10.06)
50.89
(9.61)
49.96
(9.71)
51.87
(9.41)
51.18
(10.15)
50.06
(9.67)
52.33
(10.50)
50.67
(10.35)
49.21
(9.89)
52.15
(10.60)
50.09
(10.06)
48.88
(9.98)
51.28
(10.01)
48.31
(9.84)
47.42
(9.63)
49.13
(9.97)
48.38
(9.64)
46.54
(9.46)
49.69
(9.56)
Nausea/vomiting 50.00
(10.00)
49.96
(10.27)
50.04
(9.74)
52.11
(12.70)
53.27
(14.14)
50.90
(10.86)
52.11
(11.88)
52.28
(12.40)
51.94
(11.33)
50.06
(9.97)
49.42
(9.16)
50.71
(10.69)
49.07
(8.31)
48.48
(7.59)
49.65
(8.93)
48.16
(7.09)
47.57
(6.00)
48.70
(7.93)
47.79
(6.36)
47.00
(4.33)
48.36
(7.43)
Pain 50.00
(10.00)
49.35
(9.74)
50.61
(10.20)
49.17
(9.83)
49.25
(10.01)
49.09
(9.63)
49.87
(10.15)
49.79
(9.96)
49.95
(10.35)
50.06
(10.21)
49.41
(9.84)
50.71
(10.52)
50.80
(10.15)
49.79
(9.85)
51.80
(10.35)
49.87
(9.92)
49.30
(9.42)
50.39
(10.33)
50.39
(9.69)
48.44
(9.06)
51.77
(9.88)
Dyspnoea 50.00
(10.00)
49.54
(10.01)
50.44
(9.97)
49.12
(9.67)
49.52
(10.39)
48.70
(8.84)
49.50
(9.98)
49.00
(10.09)
50.01
(9.85)
49.18
(9.87)
48.50
(9.55)
49.88
(10.14)
50.01
(9.90)
49.40
(9.69)
50.62
(10.08)
50.53
(9.98)
50.24
(9.90)
50.80
(10.05)
51.98
(10.38)
51.00
(10.18)
52.68
(10.47)
Sleep problems 50.00
(10.00)
48.97
(9.82)
50.97
(10.08)
48.52
(9.92)
47.40
(9.86)
49.68
(9.85)
50.31
(10.25)
49.77
(10.20)
50.86
(10.28)
50.56
(10.23)
49.76
(9.95)
51.36
(10.45)
51.27
(10.45)
49.70
(10.14)
52.81
(10.52)
49.89
(9.64)
48.88
(9.31)
50.83
(9.85)
49.75
(9.17)
48.64
(8.86)
50.54
(9.31)
Appetite loss 50.00
(10.00)
49.69
(9.84)
50.30
(10.14)
51.95
(11.24)
52.52
(11.78)
51.34
(10.61)
51.71
(11.05)
51.63
(10.91)
51.78
(11.20)
49.84
(9.85)
48.96
(8.92)
50.73
(10.64)
49.19
(9.23)
48.52
(8.85)
49.85
(9.55)
48.41
(8.72)
47.83
(7.98)
48.95
(9.33)
48.28
(8.47)
47.24
(7.53)
49.02
(9.01)
Constipation 50.00
(10.00)
49.62
(9.70)
50.36
(10.26)
51.40
(10.69)
51.34
(10.95)
51.46
(10.41)
51.44
(10.78)
50.69
(10.51)
52.22
(11.01)
49.72
(10.01)
49.03
(9.27)
50.42
(10.66)
49.41
(9.50)
48.56
(8.93)
50.24
(9.97)
48.59
(9.01)
48.38
(8.62)
48.79
(9.35)
48.97
(9.23)
48.98
(8.64)
48.95
(9.62)
Diarrhoea 50.00
(10.00)
50.53
(10.34)
49.50
(9.64)
51.21
(11.12)
52.64
(12.00)
49.71
(9.90)
52.01
(11.11)
52.70
(11.39)
51.31
(10.78)
50.15
(10.10)
50.72
(10.40)
49.56
(9.76)
49.58
(9.59)
49.60
(9.73)
49.55
(9.46)
48.22
(8.21)
48.41
(8.14)
48.05
(8.27)
48.36
(8.41)
47.74
(7.22)
48.80
(9.14)
Financial difficulties 50.00
(10.00)
49.90
(9.84)
50.10
(10.15)
50.25
(10.52)
51.32
(10.96)
49.13
(9.92)
51.07
(10.86)
50.96
(10.78)
51.20
(10.94)
50.83
(10.66)
50.22
(10.14)
51.45
(11.13)
50.24
(9.86)
49.45
(9.19)
51.01
(10.42)
48.92
(9.07)
48.56
(8.71)
49.24
(9.38)
48.45
(8.25)
47.92
(7.51)
48.82
(8.72)
Overall HRQoL 50.00
(10.00)
50.83
(10.01)
49.21
(9.93)
51.11
(10.05)
52.28
(10.58)
49.89
(9.32)
49.66
(9.87)
50.46
(9.82)
48.85
(9.86)
49.26
(9.96)
49.95
(9.57)
48.55
(10.30)
49.13
(10.33)
49.84
(10.35)
48.44
(10.26)
50.17
(9.96)
50.44
(9.59)
49.92
(10.29)
50.46
(9.64)
51.77
(9.55)
49.53
(9.60)
EORTC CAT Z The computer-adaptive test of the European Organisation for Research and Treatment of Cancer; EU Z European Union; HRQoL Z health-related quality of life.
a The European general population has a mean T-score of 50 (SD Z 10).
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Table 4
Country-specific EORTC CAT Core T-scorea distributions.
Domain AUT,
M (SD)
CAN,
M (SD)
DNK,
M (SD)
FRA,
M (SD)
DEU,
M (SD)
HUN,
M (SD)
ITA,
M (SD)
NLD,
M (SD)
POL,
M (SD)
RUS,
M (SD)
ESP,
M (SD)
SWE,
M (SD)
TUR,
M (SD)
GBR,
M (SD)
USA,
M (SD)
Partial h2
Physical function 52.31
(9.20)
50.19
(10.02)
50.46
(10.01)
51.24
(9.71)
48.33
(10.64)
51.30
(8.84)
50.37
(8.61)
52.74
(9.54)
48.34
(8.35)
44.69
(6.85)
51.35
(9.42)
52.33
(9.16)
46.76
(6.77)
49.02
(11.71)
49.18
(12.66)
.054
Role function 52.91
(8.39)
50.04
(9.91)
49.55
(9.99)
51.42
(9.35)
49.13
(10.76)
51.66
(8.25)
50.59
(9.55)
52.52
(9.30)
48.33
(9.12)
47.35
(8.51)
50.02
(9.14)
52.31
(8.45)
47.30
(8.41)
48.57
(11.33)
49.14
(11.49)
.029
Emotional function 52.35
(8.97)
50.76
(9.53)
51.95
(10.62)
51.62
(9.89)
50.63
(9.92)
49.67
(8.89)
48.49
(9.22)
53.47
(9.31)
47.27
(9.80)
47.21
(8.83)
50.77
(9.53)
51.14
(9.08)
45.76
(9.33)
48.60
(11.07)
50.50
(11.08)
.040
Cognitive function 52.13
(8.71)
49.62
(9.79)
49.66
(10.31)
51.14
(9.35)
50.27
(10.34)
49.75
(9.02)
50.33
(9.38)
52.83
(8.75)
47.90
(10.02)
46.51
(8.79)
50.29
(9.38)
50.77
(9.02)
45.58
(10.05)
48.19
(11.31)
48.67
(11.61)
.028
Social function 53.05
(7.81)
49.54
(10.67)
50.00
(10.46)
51.80
(9.03)
49.93
(10.07)
51.25
(8.42)
50.35
(9.20)
52.89
(8.27)
46.63
(10.53)
47.67
(9.77)
50.77
(9.65)
52.48
(8.46)
47.62
(10.17)
47.72
(11.44)
48.22
(11.57)
.033
Fatigue 48.39
(9.35)
50.03
(9.28)
50.46
(10.57)
48.77
(10.20)
51.17
(10.54)
49.99
(8.71)
49.22
(9.45)
47.48
(9.49)
52.44
(8.20)
53.79
(8.69)
48.30
(9.49)
48.91
(8.82)
53.65
(8.79)
51.18
(10.79)
50.86
(10.93)
.035
Nausea/vomiting 47.44
(5.77)
50.30
(9.95)
51.35
(10.88)
48.87
(8.76)
49.96
(10.34)
49.43
(8.72)
50.79
(10.34)
48.13
(6.89)
51.11
(10.98)
51.42
(10.11)
49.49
(9.34)
48.83
(7.66)
54.32
(12.08)
51.10
(11.39)
52.51
(12.36)
.018
Pain 48.36
(8.98)
50.38
(9.74)
50.25
(9.97)
48.64
(9.45)
50.84
(10.91)
50.21
(8.83)
49.06
(9.20)
47.48
(8.79)
51.95
(9.19)
52.10
(9.27)
50.31
(9.35)
48.71
(9.32)
52.03
(8.83)
50.73
(11.15)
51.27
(10.96)
.016
Dyspnoea 46.91
(8.69)
49.98
(9.93)
48.46
(9.54)
48.95
(9.70)
50.72
(10.89)
48.33
(8.56)
51.59
(9.65)
47.87
(8.80)
50.08
(9.32)
52.95
(9.32)
48.66
(9.19)
50.72
(7.73)
52.54
(9.41)
50.77
(10.89)
51.25
(11.29)
.026
Sleep problems 48.70
(9.67)
51.62
(10.01)
50.47
(9.94)
49.22
(9.99)
50.96
(10.99)
48.72
(8.78)
48.25
(8.81)
48.40
(8.87)
50.57
(9.47)
51.47
(9.45)
49.23
(9.19)
48.80
(8.64)
51.82
(8.71)
52.33
(10.68)
51.46
(10.66)
.017
Appetite loss 46.87
(7.20)
50.25
(10.20)
51.09
(10.87)
49.06
(9.28)
49.92
(10.26)
49.12
(8.69)
49.51
(9.26)
47.36
(7.50)
51.78
(10.76)
51.75
(10.04)
49.45
(9.52)
49.17
(9.00)
56.34
(11.09)
52.11
(11.40)
51.84
(11.35)
.035
Constipation 47.27
(8.26)
50.35
(10.14)
49.79
(10.16)
49.24
(9.35)
48.96
(10.05)
50.74
(9.04)
50.49
(9.80)
46.45
(7.56)
52.82
(10.63)
53.16
(9.75)
51.15
(9.96)
47.77
(9.04)
55.19
(11.07)
50.65
(10.74)
51.88
(11.75)
.045
Diarrhoea 48.43
(8.52)
51.32
(10.40)
50.51
(10.15)
48.63
(8.86)
49.87
(10.33)
50.14
(9.62)
50.25
(10.02)
48.04
(8.28)
51.99
(11.05)
52.09
(10.88)
49.59
(9.41)
48.83
(8.44)
53.57
(11.09)
51.22
(10.82)
52.06
(11.57)
.016
Financial difficulties 47.12
(7.66)
50.46
(10.96)
50.41
(10.44)
47.99
(8.63)
50.04
(10.23)
51.62
(10.47)
50.15
(9.64)
46.97
(7.10)
53.38
(10.81)
54.32
(11.22)
49.73
(9.35)
47.22
(7.58)
54.93
(11.05)
51.25
(11.41)
52.60
(12.23)
.055
Overall HRQoL 54.65
(9.78)
49.89
(9.54)
50.81
(11.01)
50.74
(9.27)
50.49
(10.04)
49.82
(9.40)
49.13
(9.32)
55.79
(9.81)
47.10
(9.11)
46.91
(8.79)
50.34
(9.89)
51.74
(10.47)
47.33
(10.22)
48.50
(10.80)
49.19
(10.49)
.059
Country codes: AUTZ Austria; CANZCanada; DEUZ Germany; DNKZ Denmark; FRAZ France; HUNZ Hungary; ITAZ Italy; NLDZ the Netherlands; POLZ Poland; RUSZ Russia;
ESP Z Spain; SWEZSweden; TUR Z Turkey; GBR Z United Kingdom, USA Z United Stated of America.
EORTC CAT Z The computer-adaptive test of the European Organisation for Research and Treatment of Cancer; HRQoL Z health-related quality of life.
a T-scores showed statistically significant differences (P < .001) between countries in each EORTC CAT Core domain.
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support the notion that our data are suitable to establish
the ‘European CAT Norm’ as well as valid norm scores
for the 15 countries included in our study. Second, using
online panels, we were able to collect a large database of
N Z 15,386 covering 15 countries and balanced by sex
and age groups from 18 to 70þ years. This large sample
size enabled detailed DIF analyses and precise T-score
transformations. Of note, using linear transformation to
transform z-scores to T-scores based on general popu-
lation data, in which a substantial proportion of par-
ticipants have ‘perfect’ scores (e.g. no pain), leads to
distributional properties of the T-scores that do not
follow a normal distribution. Linear transformation into
T-scores is the current standard and also used by, for
example, Patient-Reported Outcomes Measurement In-
formation System (PROMIS) [34]. However, these spe-
cific distributional properties of the T-scores need to be
kept in mind when interpreting the scores. Finally, for
practical reasons, we were only able to collect data on
item subsets from each EORTC CAT Core item bank. It
was not feasible to collect data on 262 items as this
would bring other problems such as respondent burden.
We have to assume that selected items are representative
for the full item banks. As the included items were
carefully selected based on each item’s psychometric
properties and content validity considerations, the data
presented herein are robust, state-of-the-art general
population norm data for the EORTC CAT Core.
5. Conclusions
In this article, we present representative general popu-
lation data for the cancer-specific computer-adaptive
PRO assessment system EORTC CAT Core across 11
EU countries, Russia, Turkey, Canada and the United
States. By defining the ‘European CAT Norm’, that is, a
common European Norm for the EORTC CAT Core,
scores from cancer patients obtained via this new in-
strument can be easily interpreted. In addition, EORTC
CAT Core norm scores are provided for age-, sex- and
country-specific subpopulations in 15 countries allowing
for meaningful score interpretation and comparisons
across countries and cultures.
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